27 Recruiting Studies Using Tucatinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Tucatinib
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
📍 University of Colorado — Aurora, Colorado
Breast Cancer
View Study & Checklist ➔First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
📍 California Cancer Associates for Research and Excellence — Encinitas, California
Advanced Cancer
View Study & Checklist ➔Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
📍 University of South Alabama Health Children's and Women's Hospital — Mobile, Alabama
HER2-positive Breast Cancer
View Study & Checklist ➔Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
📍 University of Colorado Cancer Center — Aurora, Colorado
HER2-positive Metastatic Breast Cancer
View Study & Checklist ➔A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
📍 Research Site — Fort Myers, Florida
Metastatic Breast Cancer
View Study & Checklist ➔A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
📍 Banner-University Medical Center Tucson Campus — Tucson, Arizona
Breast Neoplasms
View Study & Checklist ➔A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
📍 Mayo Clinic Hospital — Phoenix, Arizona
HER2 Positive Breast Cancer
View Study & Checklist ➔Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
📍 Mayo Clinic Hospital — Phoenix, Arizona
Colorectal Carcinoma
View Study & Checklist ➔Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
📍 University of California San Francisco — San Francisco, California
Brain Metastases
View Study & Checklist ➔A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
📍 Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) — Basking Ridge, New Jersey
Metastatic Breast Cancer
View Study & Checklist ➔Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
📍 HonorHealth — Phoenix, Arizona
Uterine Neoplasms
View Study & Checklist ➔ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
📍 MD Anderson Cancer Center — Houston, Texas
Dynamic Tumor Resistance
View Study & Checklist ➔Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
📍 Maryland Oncology Hematology — Columbia, Maryland
Breast Cancer
View Study & Checklist ➔PRE-I-SPY Phase I/Ib Oncology Platform Program
📍 The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center — Birmingham, Alabama
HER2-positive Breast Cancer
View Study & Checklist ➔Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
📍 Cross Cancer Institute — Edmonton, Alberta
Lymphoma, Non-Hodgkin
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
📍 Palo Verde Hematology Oncology — Glendale, Arizona
Colorectal Neoplasms
View Study & Checklist ➔A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Adenocarcinoma of the Rectum
View Study & Checklist ➔Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
📍 The Ottawa Hospital — Ottawa, Ontario
HER2-positive Breast Cancer
View Study & Checklist ➔The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Breast Cancer Female
View Study & Checklist ➔RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
📍 The West Clinic, PC dba West Cancer Center — Germantown, Tennessee
HER2-positive Breast Cancer
View Study & Checklist ➔TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
📍 University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
Lymphoma, Non-Hodgkin
View Study & Checklist ➔A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Solid Tumor
View Study & Checklist ➔Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
📍 University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
Breast Neoplasms
View Study & Checklist ➔